Aagaard, T;
Reekie, J;
Roen, A;
Daugaard, G;
Specht, L;
Sengeløv, H;
Mocroft, A;
... Helleberg, M; + view all
(2020)
Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: the CSR FENCE score.
International Journal of Cancer
, 146
(2)
pp. 321-328.
10.1002/ijc.32249.
Preview |
Text
Aagaard_et_al-2019-International_Journal_of_Cancer.pdf - Accepted Version Download (355kB) | Preview |
Abstract
The absolute risk reduction by prophylaxis in chemotherapy-induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2-6. A prediction score for risk of FN during the first cycle has recently been published1 . Patients with solid cancers initiating first-line chemotherapy in 2010-2016 were included. Cycle-specific risk factors were assessed by Poisson regression using generalised estimating equations and random split-sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum- or taxane-containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia, and not receiving granulocyte colony-stimulating factors. Each predictor added between -2 to 8 points to each patient's score (median score 4; interquartile range, 1-6). The incidence rate ratios for developing FN in the intermediate (score 1-4), high (score 5-6), and very high risk groups (score ≥7) were 7.8 (95% CI, 2.4-24.9), 18.6 (95% CI, 5.9-58.8), and 51.7 (95% CI, 16.5-162.3) compared to the low risk group (score ≤0), respectively. The score had good discriminatory ability with a Harrell's C-statistic of 0.78 (95% CI, 0.76-0.80) in the derivation and 0.75 (95% CI, 0.72-0.78) in the validation cohort (patient n=2,295, cycle n=7,670). The CSR FENCE score is the first published method to estimate cycle-specific risk of FN. This article is protected by copyright. All rights reserved.
| Type: | Article |
|---|---|
| Title: | Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: the CSR FENCE score |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/ijc.32249 |
| Publisher version: | https://doi.org/10.1002/ijc.32249 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | cancer, chemotherapy, febrile neutropenia, g-csf, infection, prediction, prophylaxis, risk score |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10070278 |
Archive Staff Only
 |
View Item |
